Document Type
Article
Publication Date
9-19-2024
Publication Title
Frontiers in Cell and Developmental Biology
Abstract
Apoptosis is an evolutionarily conserved cell death pathway that plays a crucial role in maintaining tissue homeostasis, orchestrating organismal development, and eliminating damaged cells. Dysregulation of apoptosis can contribute to the pathogenesis of malignant tumors and neurodegenerative diseases. Anticancer drugs typically possess the capacity to induce apoptosis in tumor cells. The Bcl-2 protein family, consisting of 27 members in humans, serves as the key regulator of mitochondrial function. This family can be divided into two functional groups: anti-apoptotic proteins (e.g., Bcl-2, Bcl-xl, Mcl-1) and pro-apoptotic proteins (e.g., Bad, Bax). Mcl-1 exerts its function by binding pro-apoptotic Bcl-2 proteins thereby preventing apoptosis induction. Overexpression of Mcl-1 not only correlates closely with tumorigenesis but also associates significantly with resistance towards targeted therapy and conventional chemotherapy. Effective induction of apoptosis can be achieved through inhibition or interference with Mcl-1. Thus, this mini review discusses existing Mcl-1 inhibitors.
PubMed ID
39372954
Volume
12
Chapter Title
1408107 - Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Dong, Shengli and Alahari, Suresh K., "Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy" (2024). School of Medicine Faculty Publications. 3000.
https://digitalscholar.lsuhsc.edu/som_facpubs/3000
10.3389/fcell.2024.1408107